News stories about Illumina (NASDAQ:ILMN) have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Illumina earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the life sciences company an impact score of 46.9372830181244 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- Illumina, Inc. (ILMN) Rating Lowered to Sell at BidaskClub (americanbankingnews.com)
- Zacks: Analysts Expect Illumina, Inc. (ILMN) to Post $1.00 EPS (americanbankingnews.com)
- Illumina Inc (ILMN) Moves Above Ichimoku Cloud – Evergreen Caller (evergreencaller.com)
- Is Now the Time to Capitalize on Illumina, Inc. (NASDAQ:ILMN) or TE Connectivity Ltd. (NYSE:TEL)? – FLBC News (flbcnews.com)
- These 5 underloved stocks deserve your attention (marketwatch.com)
ILMN has been the subject of several recent research reports. Vetr lowered Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price objective for the company. in a report on Wednesday, June 21st. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $195.00 price objective for the company in a report on Thursday, July 27th. Canaccord Genuity raised Illumina from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $170.00 to $215.00 in a report on Monday, August 7th. First Analysis raised Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price objective for the company in a report on Wednesday, August 2nd. Finally, Barclays PLC reissued an “equal weight” rating and issued a $150.00 price objective on shares of Illumina in a report on Wednesday, August 9th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $177.01.
Shares of Illumina (ILMN) traded down 0.98% during mid-day trading on Friday, hitting $189.32. The stock had a trading volume of 882,072 shares. Illumina has a 12 month low of $119.37 and a 12 month high of $199.95. The stock’s 50-day moving average is $181.43 and its 200 day moving average is $174.88. The company has a market cap of $27.64 billion, a PE ratio of 37.99 and a beta of 0.83.
Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. During the same quarter last year, the business posted $0.86 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. On average, equities research analysts forecast that Illumina will post $3.65 earnings per share for the current fiscal year.
In related news, SVP Charles Dadswell sold 145 shares of the stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $184.75, for a total transaction of $26,788.75. Following the completion of the transaction, the senior vice president now directly owns 10,791 shares of the company’s stock, valued at $1,993,637.25. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $194.73, for a total value of $3,894,600.00. Following the transaction, the director now directly owns 539,176 shares of the company’s stock, valued at $104,993,742.48. The disclosure for this sale can be found here. Insiders have sold 154,010 shares of company stock valued at $27,840,615 in the last quarter. 1.60% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Illumina (ILMN) Receiving Somewhat Positive Press Coverage, Study Finds” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/08/20/illumina-ilmn-receiving-somewhat-positive-press-coverage-study-finds.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.